Caladrius Biosciences, Inc. (CLBS) Analysts See $-0.83 EPS

March 9, 2018 - By Michael Pereira

 Caladrius Biosciences, Inc. (CLBS) Analysts See $ 0.83 EPS

Analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS) to report $-0.83 EPS on March, 16.They anticipate $0.10 EPS change or 13.70 % from last quarter’s $-0.73 EPS. After having $-0.38 EPS previously, Caladrius Biosciences, Inc.’s analysts see 118.42 % EPS growth. The stock decreased 6.28% or $0.36 during the last trading session, reaching $5.37. About 165,825 shares traded or 96.44% up from the average. Caladrius Biosciences, Inc. (NASDAQ:CLBS) has declined 9.24% since March 9, 2017 and is downtrending. It has underperformed by 25.94% the S&P500.

Caladrius Biosciences, Inc. (NASDAQ:CLBS) Ratings Coverage

Among 4 analysts covering Caladrius Biosciences (NASDAQ:CLBS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Caladrius Biosciences had 13 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, September 6 by H.C. Wainwright. The firm earned “Hold” rating on Friday, January 8 by Benchmark. H.C. Wainwright maintained Caladrius Biosciences, Inc. (NASDAQ:CLBS) rating on Friday, January 19. H.C. Wainwright has “Buy” rating and $7.0 target. The stock of Caladrius Biosciences, Inc. (NASDAQ:CLBS) earned “Buy” rating by H.C. Wainwright on Friday, July 21. The rating was downgraded by Maxim Group to “Hold” on Thursday, January 7. On Tuesday, August 23 the stock rating was initiated by Chardan Capital Markets with “Buy”. H.C. Wainwright maintained Caladrius Biosciences, Inc. (NASDAQ:CLBS) on Tuesday, March 6 with “Buy” rating. H.C. Wainwright maintained the shares of CLBS in report on Friday, August 11 with “Buy” rating. The stock of Caladrius Biosciences, Inc. (NASDAQ:CLBS) has “Buy” rating given on Tuesday, December 22 by Maxim Group. H.C. Wainwright downgraded Caladrius Biosciences, Inc. (NASDAQ:CLBS) on Friday, January 8 to “Neutral” rating.

More notable recent Caladrius Biosciences, Inc. (NASDAQ:CLBS) news were published by: Globenewswire.com which released: “Caladrius Biosciences Announces Completion of Enrollment of Phase 2 T-Rex …” on January 18, 2018, also Seekingalpha.com with their article: “The Strange Case Of Caladrius Biosciences” published on April 17, 2017, Globenewswire.com published: “Caladrius Biosciences Reports Interim Analysis for Phase 2 T-Rex Trial of …” on March 08, 2018. More interesting news about Caladrius Biosciences, Inc. (NASDAQ:CLBS) were released by: Marketwatch.com and their article: “Caladrius Biosciences Inc.” published on January 10, 2016 as well as Globenewswire.com‘s news article titled: “Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell …” with publication date: March 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.